Tang Capital Management LLC Bio Atla, Inc. Transaction History

Tang Capital Management LLC

$1.17 Billion
Q3 2024

A detailed history of Tang Capital Management LLC transactions in Bio Atla, Inc. stock. As of the latest transaction made, Tang Capital Management LLC holds 874,076 shares of BCAB stock, worth $559,408. This represents 0.13% of its overall portfolio holdings.

Number of Shares

874,076

Previous 1,374,076 36.39%

Holding current value

$559,408

Previous $1.88 Million 18.28%

% of portfolio

0.13%

Previous 0.23%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.17 - $2.05 $585,000 - $1.02 Million	-500,000 Reduced 36.39%	874,076 $1.54 Million
Q2 2024 Aug 14, 2024	SELL	$1.37 - $3.92 $137,000 - $392,000	-100,000 Reduced 6.78%	1,374,076 $1.88 Million
Q1 2024 May 15, 2024	SELL	$1.88 - $3.46 $1.97 Million - $3.63 Million	-1,050,000 Reduced 41.6%	1,474,076 $5.07 Million
Q4 2023 Feb 14, 2024	SELL	$1.27 - $3.18 $1.46 Million - $3.66 Million	-1,150,000 Reduced 31.3%	2,524,076 $6.21 Million
Q2 2023 Aug 14, 2023	BUY	$2.83 - $3.87 $141,500 - $193,500	50,000 Added 1.38%	3,674,076 $11 Million
Q1 2023 May 15, 2023	BUY	$2.3 - $8.25 $1.15 Million - $4.13 Million	500,000 Added 16.0%	3,624,076 $9.71 Million
Q4 2022 Feb 14, 2023	SELL	$6.29 - $11.01 $1.57 Million - $2.74 Million	-248,924 Reduced 7.38%	3,124,076 $25.8 Million
Q2 2022 Aug 15, 2022	BUY	$2.13 - $5.38 $4.84 Million - $12.2 Million	2,273,000 Added 206.64%	3,373,000 $9.61 Million
Q1 2022 May 16, 2022	BUY	$4.38 - $18.78 $3.51 Million - $15.1 Million	802,086 Added 269.23%	1,100,000 $5.5 Million
Q4 2021 Feb 14, 2022	BUY	$19.0 - $30.95 $5.66 Million - $9.22 Million	297,914 New	297,914 $5.85 Million

Others Institutions Holding BCAB

# of Institutions

Shares Held

17.4M

Call Options Held

500

Put Options Held

33.5K

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $23.2M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tang Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tang Capital Management LLC with notifications on news.

Account

Tang Capital Management LLC Bio Atla, Inc. Transaction History